Actively Recruiting
Clinical Outcomes of Edwards Lifesciences MITRIS RESLILA Mitral Valve in the Asian Population
Led by Asan Medical Center · Updated on 2025-01-03
200
Participants Needed
1
Research Sites
327 weeks
Total Duration
On this page
Sponsors
A
Asan Medical Center
Lead Sponsor
E
Edwards Lifesciences
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the early and mid-term safety and performance of the MITRIS RESILIA mitral valve in Asian patients in a real-world setting
CONDITIONS
Official Title
Clinical Outcomes of Edwards Lifesciences MITRIS RESLILA Mitral Valve in the Asian Population
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 19 or older
- Requires mitral valve replacement due to mitral valve dysfunction
- Able to provide written consent approved by the IRB and agree to the research protocol and follow-up schedule
You will not qualify if you...
- Life expectancy less than one year from causes other than cardiovascular disease
- High risk for mitral valve replacement with predicted mortality rates of 10% or greater
- Chronic kidney disease with eGFR less than 30 mL/min/1.73m²
- Undergoing surgery for infective endocarditis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Asan Medical Center
Seoul, SONGPA-GU, South Korea
Actively Recruiting
Research Team
H
HOJIN KIM, PI
CONTACT
Y
YUKYUNG CHOI, CRA
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here